F-Prime Capital

Dinari is a company that specializes in global employee stock options and incentive management. It provides a comprehensive platform that facilitates equity management and options grants while ensuring compliance with payroll regulations, taxes, and vesting schedules. By enabling investors to gain direct exposure to stock plans and public trading, Dinari simplifies the management of employee incentives, making it easier for organizations to implement effective compensation strategies.

Toku operates an online financial platform designed for B2C companies, focusing on the automation of collections and streamlining the payment process. The platform leverages machine learning to optimize the collection of recurring payments, thereby reducing late payments and enhancing operational efficiency. Toku also provides features that allow companies to manage automatic payment methods, including inactivation and deactivation. By facilitating payment orchestration and offering account-to-account payments, Toku aims to lower payment fees and improve the overall financial operations of its clients.

Bluebird Kids Health is a pediatric healthcare provider that aims to build a healthier future for children. It offers a value-based care model, delivering comprehensive, evidence-based care tailored to each family's needs. Services include nutrition support, sleep training, treatments for common ailments, and more, all aimed at reducing medical costs and providing personalized care. The company is also developing a proprietary technology platform to streamline and enhance the clinical team's experience using AI.

Ethena provides derivative infrastructure in order to transform Ethereum into the first crypto-native yield bearing stablecoin.

Rhygaze is focused on developing a novel gene therapy aimed at restoring vision in patients affected by diseases that lead to blindness. The company's innovative technology specifically targets cone cells, which are crucial for light detection but may lose sensitivity due to various conditions. By delivering a light-sensor gene directly to these compromised cone cells, Rhygaze seeks to repair their ability to detect light, thereby offering potential vision restoration solutions for individuals suffering from blindness.

Tenvie Therapeutics is a biotechnology company founded to improve patients' lives with neurological, cardiometabolic, and ophthalmic diseases. The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics. Tenvie is progressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function.

Albert Invent offers an end-to-end platform that integrates electronic lab notebooks, laboratory information management systems, and AI tools for modern materials science R&D. The platform enhances collaboration, data management, and regulatory compliance while accelerating innovation in chemical research.

Teleo specializes in transforming existing heavy machinery into remote-controlled robots, allowing operators to control equipment from a significant distance. By retrofitting current fleets with its advanced supervised autonomy technology, Teleo enables operators to seamlessly switch between machines and job sites, enhancing both productivity and safety. The company's approach allows machine operators to work from remote operation centers rather than being confined to the equipment's cabin, ultimately improving operational efficiency and providing valuable insights into job site conditions.

Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.

Space and Time is a decentralized analytics platform designed to facilitate low-latency queries and tamperproof analytics across the Web. It serves as a multichain data solution for developers and decentralized applications in sectors such as gaming and decentralized finance. The platform enables the integration of on-chain and off-chain data, allowing users to conduct complex queries through a single interface. By transforming major blockchains into advanced databases, Space and Time provides companies with enhanced analytics capabilities, ensuring faster and more reliable insights at an enterprise scale. This innovative approach positions Space and Time as a vital resource for projects requiring next-generation analytics in a decentralized environment.

Amber Therapeutics is a biotechnology company that specializes in developing advanced bioelectrical therapies aimed at treating functional disorders of the peripheral nervous system. The company creates a bioelectronic platform that delivers closed-loop bioelectrical treatments, which can sense and adapt to the patient's needs while also providing stimulation. By focusing on conditions such as mixed urinary incontinence, Amber Therapeutics seeks to enhance clinical efficacy and patient outcomes through innovative approaches that emphasize the peripheral nervous system rather than the central nervous system. Its technology has the potential to significantly improve treatment methods and overall patient care in targeted disease areas.

Xaira Therapeutics is an integrated biotechnology company focused on revolutionizing drug discovery and development through the application of artificial intelligence. Headquartered in the San Francisco Bay Area, Xaira combines expertise in machine learning, extensive biological and clinical data generation, and robust therapeutic product development. By harnessing advanced AI techniques, the company aims to enhance the understanding of biological processes and improve the effectiveness of therapies. Xaira's approach encompasses all stages of drug discovery, striving to transform how diseases are treated and enabling clients to deliver innovative therapeutic solutions.

Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of oral and injectable treatment options, including incretin, non-incretin, and combination therapies. These treatments are designed to address multiple therapeutic targets, positioning Metsera to meet the evolving demands of the weight loss treatment landscape. Additionally, Metsera integrates proprietary health technology tools to provide personalized care, enhancing the effectiveness of its therapeutic offerings.

Toku operates an online financial platform designed for B2C companies, focusing on the automation of collections and streamlining the payment process. The platform leverages machine learning to optimize the collection of recurring payments, thereby reducing late payments and enhancing operational efficiency. Toku also provides features that allow companies to manage automatic payment methods, including inactivation and deactivation. By facilitating payment orchestration and offering account-to-account payments, Toku aims to lower payment fees and improve the overall financial operations of its clients.

Teleo specializes in transforming existing heavy machinery into remote-controlled robots, allowing operators to control equipment from a significant distance. By retrofitting current fleets with its advanced supervised autonomy technology, Teleo enables operators to seamlessly switch between machines and job sites, enhancing both productivity and safety. The company's approach allows machine operators to work from remote operation centers rather than being confined to the equipment's cabin, ultimately improving operational efficiency and providing valuable insights into job site conditions.

OnCusp Therapeutics is a biopharmaceutical company focused on developing innovative oncology therapies aimed at improving treatments for cancer patients worldwide. Founded by Bing Yuan, Eric Slosberg, and Andy Fu, the company is dedicated to translating cutting-edge research into clinical applications. It specializes in advancing preclinical drug candidates to the clinical proof-of-concept stage, enabling a swift transition into global early clinical development. By prioritizing this process, OnCusp Therapeutics aims to accelerate the innovation of oncology medications, ultimately providing critical support and hope to those affected by cancer.

Shinobi Therapeutics specializes in the development of cell therapies that leverage hypoimmune CD8αβ iPS-T cells to interact with the immune system for the treatment of cancer and various genetic diseases. The company's innovative approach incorporates advanced immune evasion technology to enhance the effectiveness and accessibility of these therapies. By focusing on durable responses and the potential for redosing, Shinobi aims to reduce costs and improve patient outcomes in the healthcare sector.

ARTBIO is a clinical-stage biotechnology company focused on developing innovative alpha radioligand therapies for cancer treatment. By utilizing radioligand therapy, ARTBIO aims to deliver alpha or beta emitters that target and disrupt cancer cell DNA, offering a new approach to oncology. The company is committed to creating a supportive ecosystem that enhances the efficacy of its therapeutics, thereby enabling medical professionals to utilize novel mechanisms in cancer care. Through its advancements, ARTBIO seeks to transform the landscape of cancer treatment and improve patient outcomes.

T-Therapeutics is a biopharmaceutical company specializing in the development of engineered soluble biologics for oncological and immunological conditions. The company utilizes a proprietary T cell receptor (TCR) discovery platform, which is based on a highly humanized mouse model. This innovative approach allows T-Therapeutics to identify TCRs that target human antigens not obtainable from human samples. The TCRs bind specific pMHC targets on target cells, facilitating the recruitment of T cells to either attack cancer cells or modulate immune responses. By leveraging advanced techniques in mouse genome engineering, single cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance treatment options for patients suffering from chronic and infectious diseases while fostering a culture of creativity and collaboration within its operations.

Warmly, Inc. is a software company that provides an autonomous revenue orchestration platform tailored for small and midsize business (SMB) revenue teams. Established in 2019 and based in Redwood City, California, Warmly's platform utilizes metadata from sales enablement tools, B2B intent data, and enrichment tools to identify and connect with website visitors primed for conversion. By aggregating and integrating insights from various sources, the platform enables users to efficiently track leads, prevent customer churn, cross-sell into new departments, and facilitate warm introductions. This comprehensive approach helps sales teams engage in meaningful conversations with qualified prospects, ultimately enhancing their lead generation and sales effectiveness.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

Adcentrx Therapeutics is a biotechnology company dedicated to advancing the development of protein conjugate therapeutics aimed at treating cancer and other serious diseases. The company focuses on creating targeted therapies that leverage the precise targeting capabilities of biologics combined with the therapeutic effectiveness of small molecule payloads. Through its innovative approach, Adcentrx seeks to enhance patient treatment options, offering next-generation therapies that aim to improve outcomes for individuals facing life-threatening conditions.

SpectrumAi is a digital health company focused on enhancing Autism care by increasing access to high-quality Applied Behavior Analysis (ABA) therapy for children globally. The company collaborates with clinical leaders in ABA therapy, parents, and payers to modernize treatment approaches. SpectrumAi's healthcare technology offers objective data and meaningful insights, providing actionable guidance that empowers patients to work towards independent living, meaningful relationships, lifelong vocation, and self-advocacy. Through its innovative solutions, SpectrumAi aims to provide alternatives for life-changing therapies, ultimately improving outcomes for individuals on the autism spectrum.

Zus Health is a healthcare technology company founded in 2020 in Watertown, Massachusetts, by Jonathan Bush. The company develops a healthcare data platform aimed at accelerating digital health initiatives. Its platform uniquely integrates health and non-health data, offering a comprehensive view of patients while facilitating the sharing of clinical and non-clinical information across different applications. This approach empowers healthcare professionals to create customized digital technologies and services that are more affordable and accessible, addressing the common barriers in the healthcare sector. Zus Health is focused on fostering innovation among a new generation of healthcare builders, striving to enhance the overall health experience.

TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Elucidata Corporation, founded in 2015 and headquartered in New Delhi, India, specializes in accelerating drug discovery through its proprietary SaaS platform, Polly. This platform transforms drug discovery by delivering machine learning-ready biomedical molecular data, supported by a vast repository of over 230,000 multi-omic datasets, with more than 50,000 datasets added monthly. Polly curates this data semi-automatically, enabling data-driven drug discovery teams to integrate proprietary and public biomedical data for machine learning applications. By adhering to the FAIR guidelines, Polly's Data Lakes provide exclusive access to curated multi-omics data, facilitating faster identification of therapeutic assets with a higher likelihood of clinical success. The platform has proven instrumental in detecting validated drug targets across various fields, including immunology, oncology, and metabolomic disorders. Elucidata collaborates with leading organizations such as Pfizer, Agios Pharmaceuticals, and Genentech, as well as over 35 research partners from prominent biopharma companies and research institutions, enhancing decision-making processes in drug research and development.

Seis is an online banking platform focused on serving Spanish speakers in the United States. The platform provides a range of banking services, including savings accounts, prepaid cards for both online and offline purchases, bill payment solutions, and money transfer options. Seis also offers customizable cards to meet individual preferences and features video and chat-based customer support to enhance the banking experience. Through its comprehensive suite of services, Seis aims to deliver accessible and user-friendly banking solutions to its customers.

Latchel, Inc. is a technology company that specializes in providing an online platform for maintenance coordination tailored for property managers and landlords. Founded in 2016 and located in Bellevue, Washington, Latchel's software allows property management companies to efficiently track maintenance requests, select vendors, and enhance tenant satisfaction. The platform facilitates communication between tenants and property managers through a mobile application, enabling residents to schedule maintenance and address tasks promptly. By streamlining operations, Latchel aims to improve net margins for property managers and elevate the overall quality of maintenance services offered to residents.

Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.

Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.

CHARM Therapeutics is focused on developing innovative medicines using advanced 3D deep learning and drug discovery technologies. The company's platform aims to address undruggable disease targets, providing healthcare professionals with effective treatment options for challenging medical conditions. By leveraging cutting-edge technology, CHARM Therapeutics seeks to create transformative therapies that have the potential to significantly improve patient outcomes.

Peptone Ltd is a London-based company that specializes in developing artificial intelligence solutions aimed at addressing protein development challenges within the biotechnology, biopharmaceutical, and life sciences sectors. Established in 2016, Peptone focuses on the discovery of novel therapeutics, particularly targeting intrinsically disordered proteins. The company offers a range of services, including antibody design and optimization, a comprehensive protein database, and automated thermos-stability engineering. Its proprietary platform, CassandraAI, facilitates in silico protein engineering, enhancing the efficiency of protein development processes. Peptone's advanced protein engineering system addresses complex tasks such as anomaly detection and risk assessment, enabling clients to identify optimal strategies for resolving potential failures. This capability allows users to select suitable commercial partners to produce high-quality molecules more rapidly and cost-effectively than traditional methods employed in the pharmaceutical industry.

Teleo specializes in transforming existing heavy machinery into remote-controlled robots, allowing operators to control equipment from a significant distance. By retrofitting current fleets with its advanced supervised autonomy technology, Teleo enables operators to seamlessly switch between machines and job sites, enhancing both productivity and safety. The company's approach allows machine operators to work from remote operation centers rather than being confined to the equipment's cabin, ultimately improving operational efficiency and providing valuable insights into job site conditions.

Proof Diagnostics is a life sciences company focused on developing diagnostic tools and therapeutic applications. It specializes in creating rapid diagnostic tests, including those for detecting infectious diseases such as coronavirus. The company offers diagnostic kits that enable medical professionals to test patients efficiently, enhancing the ability to identify infections quickly. Additionally, Proof Diagnostics is working on a smart, portable system aimed at improving the detection of various infectious diseases, thereby contributing to advancements in public health and disease management.

Doceree Inc is a healthcare marketing technology company that operates a programmatic physician engagement and advertising platform. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, Doceree specializes in connecting pharmaceutical and healthcare brands with healthcare professionals (HCPs). The platform enables targeted advertising and provides data analytics to help clients effectively reach and engage with HCPs in a compliant manner. Utilizing artificial intelligence and data segmentation, Doceree identifies specific HCPs across various digital platforms, including physician networking sites, medical journals, and telemedicine platforms. This approach allows healthcare industry professionals to deliver precise and transparent messaging at scale, catering to the needs of media agencies, pharmaceutical brands, medical device companies, consumer healthcare brands, and hospitals.

Eleos Health develops innovative health technology solutions aimed at enhancing decision-making for clinicians in the behavioral health sector. The company's AI-powered Speech-to-Insights system operates during mental health sessions to analyze voice data in real time. By gathering insights on patients through this voice technology, Eleos Health enables clinicians to deliver personalized, efficient, and cost-effective care. The automated nature of the system helps streamline the clinical process, ultimately supporting mental health professionals in providing the necessary care and support for their patients.

AmplifyMD is a telemedicine platform that connects over 3,300 medical institutions, particularly in rural and underserved areas, with a network of specialists. By offering a customized telehealthcare system, AmplifyMD enables hospitals to access on-demand specialists remotely, facilitating specialty coverage through virtual care. The platform not only streamlines clinical workflows but also automates billing processes, integrating smoothly with existing electronic health records (EHRs). This service helps hospitals minimize unnecessary patient transfers and reduces the need for costly locum tenens, ultimately improving patient care and operational efficiency.

Aerium Therapeutics focuses on the discovery and development of novel monoclonal antibodies and antiviral treatments aimed at combating SARS-CoV-2 variants. The company is dedicated to creating a pipeline of biologics and small molecule antivirals, specifically designed to address pandemic and epidemic threats. Its fully integrated discovery platform utilizes a wide network of international collaborations and established research infrastructures. This approach enables the development of targeted antigens for both the treatment and prevention of COVID-19, as well as emerging variants of the virus.

Mathison is a technology company that specializes in diversity hiring and retention. Its platform provides a comprehensive solution for organizations looking to enhance their diversity, equity, and inclusion (DEI) efforts. This includes tools for top-of-funnel diversity sourcing, bias reduction in hiring processes, and strategies to engage the entire team in diversity initiatives. Mathison's services cater to a variety of clients, including well-known brands, and focus on sourcing underrepresented candidates while ensuring job seekers' identities are protected. The platform also functions as a recruitment marketplace, centralizing talent networks to facilitate personalized job opportunities and effective DEI strategy management.

Silq is a company founded in 2020 by former executives from Flexport, focusing on enhancing global manufacturing through local expertise, particularly in the apparel and home furnishing sectors. The company offers a suite of services, including production monitoring, quality assistance, and tech pack optimization. Its innovative technology provides real-time data from the factory floor, allowing production managers to improve product quality, anticipate supply chain bottlenecks, and minimize waste. By delivering insights on costing, inventory replenishment, and sales forecasting, Silq enables inventory managers to streamline operations and enhance overall efficiency in the manufacturing process.

Rialtic operates an open marketplace enterprise platform that assists payers in achieving accurate healthcare payments. The platform features a reference source repository and curated content, along with payment accuracy technology designed to help users minimize costs associated with payment accuracy. By streamlining the process, Rialtic enables payers to adapt more easily to changes in the healthcare landscape and fosters innovation in payment solutions.

Canary Technologies LLC, based in San Francisco, California, specializes in developing innovative software solutions for the hospitality industry, focusing on enhancing operational efficiency and improving guest experiences. The company's platform modernizes outdated hotel management processes by offering features such as contactless check-in, digital authorizations, electronic signatures, and a customizable amenity store. These tools are designed to streamline workflows, reduce costs, increase revenue, and enhance compliance, making them invaluable to hoteliers. Trusted by numerous prestigious hotel brands worldwide, Canary Technologies aims to drive greater productivity and minimize fraud within the sector.

Expressable is an online speech therapy practice that focuses on enhancing communication for individuals with speech and language disorders, particularly children. By employing a parent-focused care model, Expressable integrates speech therapy techniques into the daily lives of users, thereby improving outcomes and experiences. The platform offers a range of services, including therapy for accent modification, aphasia, apraxia of speech, autism spectrum disorder, and various language disorders. It facilitates consistent practice through weekly activities, enabling users to develop their communication skills effectively.

Parrot Software specializes in developing comprehensive restaurant management solutions that integrate software and hardware to optimize operations for restaurants and fast-food establishments. Its platform encompasses essential functions such as point of sale, inventory management, customer payments, ordering, seating, and data visualization. By providing back-office tools that streamline these various tasks, Parrot Software enables clients to enhance the efficiency and effectiveness of their restaurant operations. The company's focus on innovation aims to deliver superior satisfaction in both service and operational management for its customers.

K36 Therapeutics is engaged in the development of small molecule therapeutics aimed at treating cancer. The company focuses on translating epigenetic modulation of oncogenic pathways into effective therapies, utilizing technology to create orally bioavailable small molecules and selective inhibitors. This innovative approach enables healthcare professionals to enhance treatment options for cancer patients, addressing the complexities of oncogenic pathways and improving therapeutic outcomes.

AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Notabene, Inc. is a New York-based company that offers a software as a service (SaaS) platform focused on crypto compliance for the financial industry. Established in 2020, Notabene provides businesses with tools to meet emerging global regulations for cryptocurrency transactions, particularly the Travel Rule. Its platform features a unified API and a comprehensive dashboard designed to assist compliance officers in managing risks associated with both Travel Rule and non-custodial transactions. By simplifying compliance processes, Notabene enables financial companies to engage with a broader range of crypto businesses, enhancing transaction confidence and supporting growth in their operations.

Hone Group Inc., established in 2018, is a San Francisco-based company that specializes in live online leadership and management training. It offers a development platform that empowers organizations to enhance their employees' soft skills, including communication, team building, and conflict management. Hone's platform facilitates expert-led small group training, peer learning, and continuous reinforcement, while also providing data-driven insights to measure and improve training impact.

Patina is a healthcare provider focused on enhancing the aging experience for older adults and their families. The company has developed a care model that prioritizes the unique needs and values of this demographic. By offering personalized and on-demand services, Patina aims to create a healthcare experience that is both human-centered and supportive. This approach allows families to actively participate in the care of their loved ones, ensuring that older adults receive the attention and respect they deserve as they navigate the challenges of aging. Patina's mission is to empower individuals to live their best lives and maintain their dignity as they age.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Burro is a developer of an autonomous farming platform designed to enhance productivity in agricultural settings. The company creates robotic tools that autonomously follow workers and transport cargo, alleviating them of physically demanding tasks that do not add significant value. By automating these labor-intensive activities, Burro enables farmworkers to concentrate on more critical functions, ultimately improving operational efficiency. Additionally, the tools capture essential data to facilitate further automation of farm work, aligning with the long-term goal of automating tedious outdoor tasks. Through its innovative approach, Burro aims to support farmers in optimizing their operations and fostering growth.

Burro is a mobile application for Android and iOS devices that offers delivery and on-demand moving services to its users. The application enables its users to request pickups by filling up their personal information and items required. The platform offers its services to individuals and businesses. Its delivery portfolio consists of household goods, carpets, wood, and retail store items. Burro was launched in 2014 by Jason Ervin and Ethan Hurtado and is based in Texas.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Zus Health is a healthcare technology company founded in 2020 in Watertown, Massachusetts, by Jonathan Bush. The company develops a healthcare data platform aimed at accelerating digital health initiatives. Its platform uniquely integrates health and non-health data, offering a comprehensive view of patients while facilitating the sharing of clinical and non-clinical information across different applications. This approach empowers healthcare professionals to create customized digital technologies and services that are more affordable and accessible, addressing the common barriers in the healthcare sector. Zus Health is focused on fostering innovation among a new generation of healthcare builders, striving to enhance the overall health experience.

Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children's medicines to provide Chinese children and families with high-quality and affordable treatment options.

Logixboard, Inc. is a Seattle-based company established in 2016 that specializes in developing a cloud platform specifically for freight forwarders. This platform enhances transparency and communication between logistics service providers and their customers. As a white-labeled customer experience software, Logixboard allows these providers to increase sales and improve customer retention by integrating seamlessly with their existing internal systems. The implementation of Logixboard's solution can be completed in less than three weeks with minimal effort from the logistics teams. Additionally, the platform offers real-time tracking and big data analytics, equipping the supply chain and logistics sector with the necessary tools to stay competitive amidst the ongoing digitization of the industry.

Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

AppliedVR, Inc. is a Los Angeles-based company founded in 2013 that specializes in virtual reality solutions aimed at enhancing patient experiences in healthcare, particularly for pain and anxiety management. The company’s flagship product, EaseVRx, is a VR-based prescription therapeutic that has received Breakthrough Device Designation from the FDA. By integrating principles of cognitive behavioral therapy and mindfulness, EaseVRx provides a comprehensive approach to managing chronic pain, addressing biological, psychological, and social factors. This platform allows patients to self-administer treatment at home, offering flexibility and promoting better quality of life. AppliedVR has established strategic partnerships with prominent healthcare institutions, including Cedars-Sinai and Children's Hospital Los Angeles, furthering its mission to empower patients in their pain management journey.

Vendr, Inc. is a Boston-based company that specializes in a software-as-a-service (SaaS) platform designed to streamline the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr offers a comprehensive suite of services including commercial negotiations, renewal management, and contract logistics. The platform empowers finance and procurement teams by providing access to extensive data from numerous transactions, enabling them to find suitable software, negotiate favorable prices, and manage renewals effortlessly. Vendr's commitment to simplifying SaaS procurement has positioned it as a leader in the industry, further enhanced by its recent acquisition of the SaaS management platform, Blissfully.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

ConnexPay LLC is a payment solution provider based in Bonita Springs, Florida, specializing in the travel and e-commerce markets. Established in 2017, the company offers an innovative platform that enables internet merchants to accept customer payments through the issuance of single-use virtual credit cards. This technology streamlines payment processes by minimizing risks, reducing acceptance costs, and eliminating the need for large merchant reserves or lines of credit. ConnexPay's integrated solution includes powerful anti-fraud detection and PCI-certified payment acceptance and issuance, all facilitated through their patent-pending intelligent routing system. By partnering with various financial institutions, ConnexPay allows clients to efficiently manage payments to suppliers while ensuring secure transactions for customer payments. This comprehensive approach simplifies financial operations for businesses acting as intermediaries in the travel and e-commerce sectors.

Argyle develops a payroll connectivity platform that enhances financial services by providing real-time income and employment data. The platform automates various processes, including verifications, background checks, account funding, direct deposit switching, premium calculations, and wage advancements. By streamlining these functions, Argyle enables businesses and financial institutions to improve their onboarding and account management processes, thereby facilitating modern financial solutions.

Ashby is a developer of recruitment software specifically designed for high-growth companies. The company offers an enterprise-grade platform that streamlines the hiring process, making it more effective for company leaders, recruiters, and hiring managers. By providing a user-friendly solution, Ashby enables organizations of various sizes to enhance their recruitment strategies and meet their growth objectives more efficiently.

Citrine Medicine is a rare disease-focused pharmaceutical firm.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

NFlection Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of targeted therapies for rare disorders. Based in Wayne, Pennsylvania, the company primarily addresses conditions such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks like keratinocytic epidermal nevi and nevus sebaceous. NFlection specializes in treatments that target the Ras/Raf/MEK/ERK signaling pathway, which is often aberrantly activated in these disorders. One of its notable developments includes a soft mitogen-activated protein kinase (MEK) formulated as a cosmetically elegant gel for topical application, allowing for localized treatment while minimizing systemic side effects typically associated with orally administered MEK inhibitors. Founded in 2014, NFlection Therapeutics aims to improve patient outcomes through innovative therapeutic solutions.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Owkin, Inc. is an artificial intelligence company that specializes in developing software aimed at improving treatment outcomes for patients, particularly in oncology. Established in 2016, with headquarters in New York and an office in Paris, Owkin employs AI tools to enhance drug discovery and accelerate clinical trials while safeguarding patient privacy through federated learning. The company offers several products, including Owkin Lab for therapeutic data connection, Owkin Loop for validated and packaged models, and a comprehensive software stack. Owkin's portfolio includes 30 live models, with an additional 40 in development, focusing on identifying new drug candidates and elucidating the mechanisms behind treatment efficacy. Co-founded by Thomas Clozel, a clinical research doctor, and Gilles Wainrib, a machine learning expert, Owkin has raised over $255 million and achieved unicorn status due to its innovative approach in addressing unmet medical needs and optimizing the drug development process.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its proprietary Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aiming to restore normal genetic function and address the underlying causes of various diseases. By targeting a broad spectrum of conditions with significant unmet medical needs, Prime Medicine seeks to revolutionize the field of genetic medicine through effective and efficient therapeutic solutions.

AvantStay, Inc. is a hospitality company founded in 2016 and based in Los Angeles, California, specializing in vacation rental homes. The company operates a next-generation platform that redefines travel and investment experiences by offering a highly curated selection of short-term rental properties tailored to guests' needs. With a portfolio exceeding 450 premier properties across more than 60 cities, AvantStay utilizes proprietary technology to facilitate seamless bookings and efficient property management. The company has established partnerships with various online travel agencies, enabling direct bookings and enhancing accessibility for travelers. AvantStay aims to provide an elevated and authentic experience for its customers while maintaining an asset under management exceeding $800 million.

Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.

Sironax is a clinical-stage biotechnology company based in Beijing, China, founded in 2017. The company focuses on developing innovative products and treatments for age-related degenerative diseases, concentrating on mechanisms such as regulated cell death, neuroprotective pathways, and neuroinflammation. By researching apoptosis and other cell death pathways, Sironax aims to create advanced pharmaceuticals that can improve the lives of patients suffering from these conditions. Their goal is to transform the treatment landscape for age-related degenerative diseases, benefiting millions of patients and their families globally.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. The company focuses on developing novel therapeutics called "nocions," which are designed to treat conditions associated with neurogenic inflammation. These nocions specifically target activated sensory neurons, entering nociceptors through large-pore channels that open in response to stimulation. This mechanism allows for the selective blocking of sodium channels, providing targeted and sustained relief for serious conditions such as cough, itch, pain, and inflammation. By offering an alternative to traditional small molecule anesthetics, Nocion Therapeutics aims to deliver more effective treatment options for patients suffering from these debilitating symptoms.

Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.

Owkin, Inc. is an artificial intelligence company that specializes in developing software aimed at improving treatment outcomes for patients, particularly in oncology. Established in 2016, with headquarters in New York and an office in Paris, Owkin employs AI tools to enhance drug discovery and accelerate clinical trials while safeguarding patient privacy through federated learning. The company offers several products, including Owkin Lab for therapeutic data connection, Owkin Loop for validated and packaged models, and a comprehensive software stack. Owkin's portfolio includes 30 live models, with an additional 40 in development, focusing on identifying new drug candidates and elucidating the mechanisms behind treatment efficacy. Co-founded by Thomas Clozel, a clinical research doctor, and Gilles Wainrib, a machine learning expert, Owkin has raised over $255 million and achieved unicorn status due to its innovative approach in addressing unmet medical needs and optimizing the drug development process.

TreeENT Health, established in 2017 and based in Hangzhou, China, operates as a specialized surgical center focusing on ear, nose, and throat (ENT) conditions. The company, also known as Renshu Medical, provides a comprehensive range of services for various ENT diseases, including suppurative otitis media, allergic rhinitis, chronic sinusitis, and thyroid cancer. Utilizing advanced technology, TreeENT offers minimally invasive surgical procedures, as well as diagnostic services such as Danish ear hearing detection, nasal endoscopy, and nasopharyngoscopy. Additionally, the company facilitates patient access through WeChat for appointment scheduling with medical experts. With a commitment to high-quality care, TreeENT aims to deliver professional medical services that align with international standards and support personalized chronic disease rehabilitation.

Castle manages rental homes for landlords using automation and on-demand labor. It finds tenants, collect rent, and coordinate maintenance, allowing owners to kick back, relax, and never worry about their rental properties again. Owners either have to deal with this whole mess themselves, or spend 10% of their rental income on a traditional property management company that requires constant supervision and is often incentivized to act against the owner’s best interest. There are 43 million rental units in the United States, and most of them are currently managed with some combination of faxes, mail, and unreturned voicemails on the landlord’s personal phone. Castle moves all of property management into a seamless online experience, providing owners with transparency, speed, and incredible customer service—plus huge cost savings over traditional management. Renters get great service and instant updates about important issues.

Castle is a technology company that specializes in user account fraud detection and prevention for online businesses. It offers API-based solutions that enable businesses, regardless of size, to protect their customers' accounts from unauthorized access. Castle's platform tracks and analyzes user behavior in real-time, using a wide range of signals such as device fingerprints, keystroke dynamics, and browsing history. When suspicious activity is detected, both the business administrator and the account owner are promptly alerted, allowing for swift and appropriate action.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

Innovusion, Inc. is a developer of advanced image grade LiDAR sensor systems tailored for level 4 and 5 autonomous vehicles and advanced driver-assistance systems (ADAS). Founded in 2016 and based in Sunnyvale, California, the company focuses on delivering high-performance perception solutions that combine range, resolution, and hardware-accelerated sensor fusion. Their compact sensor systems are designed for ease of integration and cost-effectiveness, making them suitable for demanding applications in the autonomous driving market. Innovusion's innovative technology positions it as a key player in the rapidly evolving landscape of autonomous transportation.

Nebula Genomics is a company that focuses on human genome sequencing and health data, aiming to create a comprehensive online marketplace for genomic information. Founded in 2016 by Harvard genomics pioneer George Church and his colleagues, the company is headquartered in San Francisco, California, with additional offices in Boston, Massachusetts. Nebula Genomics utilizes blockchain technology to empower consumers by allowing them to maintain control over their genomic data and receive compensation for its use. The platform aggregates extensive genetic information, enabling researchers to analyze data for accelerated drug development and personalized medicine. The company’s DNA sequencing technology covers all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, facilitating in-depth genetic analysis and variant exploration.

Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with significant unmet medical needs. The company, based in Oakland, California, was incorporated in 2016 and is a subsidiary of Zogenix, Inc. Modis Therapeutics is advancing its lead therapy, MT1621, which aims to restore mitochondrial DNA replication fidelity. This therapeutic candidate is specifically designed to address thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disorder. By improving nucleotide balance, increasing mitochondrial DNA copy number, and enhancing cell function, Modis Therapeutics aims to provide meaningful treatment options that can prolong the lives of affected patients.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

B-One Ortho Corp. is a manufacturer of orthopedic healthcare solutions, specializing in artificial joints that facilitate joint replacement surgeries. Founded in 2015 and headquartered in Cedar Knolls, New Jersey, the company also maintains offices in Shanghai and Suzhou, China. Its notable products include the B-One total hip system, which features advanced coating technology and instrumentation, as well as the Juveno bone-conserving femoral prosthesis and primary acetabular systems. These innovations aim to enhance the effectiveness of hip and knee arthroplasty, ultimately helping patients regain their mobility and improve their quality of life.

Notable is an AI-driven platform designed to enhance healthcare operations and improve physician-patient interactions. Deployed at over 10,000 care sites, it automates more than a million repetitive workflows daily, including processes related to registration, scheduling, authorizations, and chart reviews. The platform features a voice-powered application that organizes physician-patient conversations and dictations while securely recommending appropriate billing codes. By streamlining these tasks, Notable reduces manual workload for caregivers and fosters personalized care for patients, ultimately contributing to better financial health for healthcare providers.

AvantStay, Inc. is a hospitality company founded in 2016 and based in Los Angeles, California, specializing in vacation rental homes. The company operates a next-generation platform that redefines travel and investment experiences by offering a highly curated selection of short-term rental properties tailored to guests' needs. With a portfolio exceeding 450 premier properties across more than 60 cities, AvantStay utilizes proprietary technology to facilitate seamless bookings and efficient property management. The company has established partnerships with various online travel agencies, enabling direct bookings and enhancing accessibility for travelers. AvantStay aims to provide an elevated and authentic experience for its customers while maintaining an asset under management exceeding $800 million.

Metcela Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for cardiac diseases. Founded in 2016 and based in Kawasaki, Japan, Metcela specializes in fibroblast-based treatments, particularly its lead asset, MTC001. This therapy utilizes VCAM-1-positive Cardiac Fibroblasts, which are derived from the patient's own heart cells. Rather than replacing damaged cells, the therapy enhances the body's natural healing processes to repair heart tissue and restore a favorable microenvironment. Through its research and development efforts, Metcela aims to offer patients an effective and affordable alternative for treating heart failure.

Engine by MoneyLion is a financial technology company that specializes in embedded finance and marketplace platforms for financial services. The company offers a comprehensive suite of tools, including a search, comparison, and recommendation engine for various financial products, as well as tools for offer management and optimization. These services empower businesses to integrate financial products into their operations, enabling them to deliver personalized financial offers to their clients. Additionally, Engine by MoneyLion provides a diverse range of financial services, including loans, credit, insurance, and savings account solutions.

CareStack is a company that provides an all-in-one cloud-based platform designed to streamline dental practice management. The platform integrates various functionalities including patient engagement, scheduling, telehealth conferencing, charting, automated reminders, claims and billing, and business insights. This comprehensive solution aims to enhance operational efficiency, improve patient care, and increase financial success for dental practices. CareStack's mission is to support dentists in achieving better practice management and an improved quality of life through its technology-driven offerings.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.